These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 1498070)

  • 1. Towards a molecular basis for tamoxifen resistance in breast cancer.
    Johnston SR; Dowsett M; Smith IE
    Ann Oncol; 1992 Jul; 3(7):503-11. PubMed ID: 1498070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The anti-proliferative effect of suramin towards tamoxifen-sensitive and resistant human breast cancer cell lines in relation to expression of receptors for epidermal growth factor and insulin-like growth factor-I: growth stimulation in the presence of tamoxifen.
    Boylan M; van den Berg HW; Lynch M
    Ann Oncol; 1998 Feb; 9(2):205-11. PubMed ID: 9553667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Measuring IGF-1, ER-α and EGFR expression can predict tamoxifen-resistance in ER-positive breast cancer.
    Chong K; Subramanian A; Sharma A; Mokbel K
    Anticancer Res; 2011 Jan; 31(1):23-32. PubMed ID: 21273576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Tamoxifen in the treatment of breast cancer].
    Charlier C; Colin C; Merville MP; Gielen J; Lambotte R; Plomteux G; Castronovo V
    J Gynecol Obstet Biol Reprod (Paris); 1994; 23(7):751-6. PubMed ID: 7822705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transforming growth factor beta 1 is implicated in the failure of tamoxifen therapy in human breast cancer.
    Thompson AM; Kerr DJ; Steel CM
    Br J Cancer; 1991 Apr; 63(4):609-14. PubMed ID: 2021547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of RBP2-Induced ER and IGF1R-ErbB Signaling in Tamoxifen Resistance in Breast Cancer.
    Choi HJ; Joo HS; Won HY; Min KW; Kim HY; Son T; Oh YH; Lee JY; Kong G
    J Natl Cancer Inst; 2018 Apr; 110(4):. PubMed ID: 29028222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple forms of TGF-beta 1 in breast tissues: a biologically active form of the small latent complex of TGF-beta 1.
    Baillie R; Coombes RC; Smith J
    Eur J Cancer; 1996 Aug; 32A(9):1566-73. PubMed ID: 8911119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Type I IGF receptor and acquired tamoxifen resistance in oestrogen-responsive human breast cancer cells.
    Wiseman LR; Johnson MD; Wakeling AE; Lykkesfeldt AE; May FE; Westley BR
    Eur J Cancer; 1993; 29A(16):2256-64. PubMed ID: 8110496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The functional implications of Akt activity and TGF-beta signaling in tamoxifen-resistant breast cancer.
    Yoo YA; Kim YH; Kim JS; Seo JH
    Biochim Biophys Acta; 2008 Mar; 1783(3):438-47. PubMed ID: 18164268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tamoxifen-induced ER-alpha-SRC-3 interaction in HER2 positive human breast cancer; a possible mechanism for ER isoform specific recurrence.
    Mc Ilroy M; Fleming FJ; Buggy Y; Hill AD; Young LS
    Endocr Relat Cancer; 2006 Dec; 13(4):1135-45. PubMed ID: 17158759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alternative mechanisms of action of anti-oestrogens.
    Colletta AA; Benson JR; Baum M
    Breast Cancer Res Treat; 1994; 31(1):5-9. PubMed ID: 7981456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin-like growth factor - oestradiol crosstalk and mammary gland tumourigenesis.
    Hawsawi Y; El-Gendy R; Twelves C; Speirs V; Beattie J
    Biochim Biophys Acta; 2013 Dec; 1836(2):345-53. PubMed ID: 24189571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer.
    Borg A; Baldetorp B; Fernö M; Killander D; Olsson H; Rydén S; Sigurdsson H
    Cancer Lett; 1994 Jun; 81(2):137-44. PubMed ID: 7912163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status.
    Dowsett M; Houghton J; Iden C; Salter J; Farndon J; A'Hern R; Sainsbury R; Baum M
    Ann Oncol; 2006 May; 17(5):818-26. PubMed ID: 16497822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acquired tamoxifen resistance in human breast cancer--potential mechanisms and clinical implications.
    Johnston SR
    Anticancer Drugs; 1997 Nov; 8(10):911-30. PubMed ID: 9436634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo models for endocrine-dependent breast carcinomas: special considerations of clinical relevance.
    Fichtner I; Becker M; Zeisig R; Sommer A
    Eur J Cancer; 2004 Apr; 40(6):845-51. PubMed ID: 15120040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Are breast tumours resistant to tamoxifen also resistant to pure antioestrogens?
    Wakeling AE
    J Steroid Biochem Mol Biol; 1993 Dec; 47(1-6):107-14. PubMed ID: 8274423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Down-regulation of transforming growth factor-alpha by tamoxifen in human breast cancer.
    Noguchi S; Motomura K; Inaji H; Imaoka S; Koyama H
    Cancer; 1993 Jul; 72(1):131-6. PubMed ID: 8508397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CtIP silencing as a novel mechanism of tamoxifen resistance in breast cancer.
    Wu M; Soler DR; Abba MC; Nunez MI; Baer R; Hatzis C; Llombart-Cussac A; Llombart-Bosch A; Aldaz CM
    Mol Cancer Res; 2007 Dec; 5(12):1285-95. PubMed ID: 18171986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endocrine resistance in advanced breast cancer.
    Dowsett M
    Acta Oncol; 1996; 35 Suppl 5():91-5. PubMed ID: 9142976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.